[Experience of olokizumab use in COVID-19 patients].
V N AntonovG L IgnatovaO V PribytkovaS S SleptsovaE A StrebkovaE A KhudyakovaA I SimakovaS Y RabetsE P TihonovaD Y KurmaevaM A PetrushinA S MashkovE V GayazovaI V YashevaM A AndreevV V KhinovkerA Y KarpuninB V BerezhanskiyPublished in: Terapevticheskii arkhiv (2020)
The use of olokizumab to treat the new COVID-19 coronavirus disease has demonstrated a positive effect on clinical and laboratory parameters. Primarily, it affects the severity of clinical parameters by improving the general condition already on the first day of observation, and decreasing body temperature to normal values. The changes in the C-reactive protein levels show a significant effect of the IL-6 inhibitor on the systemic inflammatory response.